upcoming news to look forward to...

I've just counted at least 15 items that we shareholders should be updated on this half of the year. I don't believe we're too far away re these. Just because we received a response re price query today doesn't mean that these items below aren't in the process of being finalised. I wouldn't want to be on the sidelines when this lot of news is announced and it'll most likely be one update after the other.

1. DSMC review on low dose cohort, before moving to higher dose for Rett Syndrome.

2. Rett Syndrome patient enrollment update.

3. Orphan Drug Designation for Rett Syndrome. This will be significant news.

4. Fragile X - initiation of Phase II trial.

5. Fragile X - At the AGM, company stated that they are preparing to submit an IND and request for Orphan Drug and Fast Track Designation to the FDA.

6. Fragile X - Peer-reviewed paper for Fragile X should be published this year. This will be an extremely important document for the company going forward.

7. Army update on NNZ-2591 for testing Fragile X in the same mouse model as NNZ-2566.

8. Fragile X Research Foundation (FRAX-DVI) update on NNZ-2591 for testing Fragile X in the same mouse model as NNZ-2566.

9. Concussion Study - Neuren/Army to determine if it is feasible to conduct the study at the Army Training Centres.

10. Finalising plan to conduct trial in military population for concussion and will be updated on when and where the study will be conducted.

11. Intrepid Trial - EFIC process 5 new sites for DOD to approve. In addition, 10 new sites are in the process of being activated and are expected to receive DOD approval in the 3rd quarter this year which will mean that 18 sites will be actively screening and enrolling, 10 under EFIC protocol.

12. Perseis - Antibodies have been screened in vitro for biological activity and binding to TFF and are undergoing final characterisation prior to progressing into an in vivo cancer model. With now 5 antibodies rather than 2 originally being evaluated, it has pushed update out a little on this front. Results from the in vivo experiments are now expected in Q3-2013.

13. NNZ-2566 - Waiting on news for 6 pending applications covering composition of matter, oral formulations and methods of use for NNZ-2566 across a wide range of possible uses.

14. NNZ-2591 - Waiting on news for 2 pending applications covering composition of matter, formulations and methods of use with remaining patent life (without extensions) between 11 and 15 years.

15. Fragile X - Peer-reviewed paper for Fragile X should be published this year. This will be an extremely important document for the company going forward.

16. Anything out of left field :-)

Tony